Selected News from Today's FirstWord

Bristol-Myers Squibb's fourth-quarter profit rises, misses estimates

Bristol-Myers Squibb's fourth-quarter profit reached $852 million, up from $483 million in the year-ago period, although the figure fell short of analysts' estimates due partly to lower-than-expected sales of Plavix. Quarterly revenue for the drug, which is marketed with Sanofi, slipped 3 percent to $1.7 billion. Full story

• Amgen’s fourth-quarter profit dips on lower anaemia drug sales - (Ref. The Wall Street Journal; NASDAQ; FOX Business; FNNO; Wall St. Cheat Sheet; Bloomberg; Amgen)
• US court allows Watson, Amphastar to market generic version of Sanofi’s Lovenox - (Ref. Bloomberg; FNNO; MarketWatch; StreetInsider; Watson)
• Amgen to buy Micromet for nearly $1.2 billion - (Ref. Los Angeles Times; The New York Times; Washington Business Journal; The Wall Street Journal; NASDAQ; Amgen; MarketWatch; Bloomberg; Yahoo!Finance)
• Celgene to acquire Avila Therapeutics in deal worth up to $925 million - (Ref. The Star-Ledger; Boston Business Journal; Xconomy; MarketWatch; NASDAQ; Business Wire)
• Analysts expect Roche to increase offer for Illumina, deal to spur further acquisitions - (Ref. BusinessWeek; The Irish Times; The Wall Street Journal; The Miami Herald; Business Wire)

Also in the News

• Products:
• afatinib,
• BeneFix,
• collagenase,
• Cozaar,
• Curosurf,
• Gas X,
• MZ-004

• Companies:
• Baxter,
• BMS,
• BTG,
• Helix BioPharma,
• Momenta,
• Roche,
• Seattle Genetics

• Markets:
• EU,
• Italy,
• United States,
• World

Most Read Stories in the Past Week

• Novartis CEO discusses plans for Diovan patent expiration
• Pfizer records 5-percent rise in second-quarter profit
• Pfizer may introduce OTC version of Lipitor, sources say
• NICE provisionally rejects Novartis' oral MS drug Gilenya
• HHS drops case against Forest CEO